This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Juffermans, N. P.
Right arrow Articles by van der Poll, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Juffermans, N. P.
Right arrow Articles by van der Poll, T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2001, p. 1547-1549, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1547-1549.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Thalidomide Inhibits Granulocyte Responses in Healthy Humans after Ex Vivo Stimulation with Bacterial Antigens

Nicole P. Juffermans,1,2 Annelies Verbon,1,2 Marc J. Schultz,1,2 C. Erik Hack,3,4 Sander J. H. van Deventer,1 Peter Speelman,2 and Tom van der Poll1,2,*

Laboratory of Experimental Internal Medicine,1 Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS,2 and Laboratory for Experimental and Clinical Immunology,3 Academic Medical Center, University of Amsterdam, and the Laboratory of Pathophysiology of Plasma Proteins, Central Laboratory of The Netherlands Red Cross Blood Transfusion Service,4 Amsterdam, The Netherlands

Received 13 July 2000/Returned for modification 29 December 2000/Accepted 29 January 2001

Ingestion of thalidomide was associated with a reduction in the upregulation of the granulocyte activation marker CD11b and a reduced capacity to release elastase and lactoferrin after stimulation with lipopolysaccharide or lipoteichoic acid. A single oral dose of thalidomide attenuates neutrophil activation upon ex vivo stimulation with bacterial antigens.

* Corresponding author. Mailing address: Laboratory of Experimental Medicine, Room G2-132, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Phone: 31-20-5669111. Fax: 31-20-6977192. E-mail: T.vanderPoll{at}amc.uva.nl.

Antimicrobial Agents and Chemotherapy, May 2001, p. 1547-1549, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1547-1549.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Gullestad, L., Ueland, T., Fjeld, J. G., Holt, E., Gundersen, T., Breivik, K., Folling, M., Hodt, A., Skardal, R., Kjekshus, J., Andreassen, A., Kjekshus, E., Wergeland, R., Yndestad, A., Froland, S. S., Semb, A. G., Aukrust, P. (2005). Effect of Thalidomide on Cardiac Remodeling in Chronic Heart Failure: Results of a Double-Blind, Placebo-Controlled Study. Circulation 112: 3408-3414 [Abstract] [Full Text]  
  • Nasca, M. R, Micali, G., Cheigh, N. H, West, L. E, West, D. P (2003). Dermatologic and Nondermatologic Uses of Thalidomide. The Annals of Pharmacotherapy 37: 1307-1320 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»